* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:RXRX vs ABSI, GLUE, ANAB: Buyback Yield % Comparison
For the Biotechnology subindustry, Recursion Pharmaceuticals's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Recursion Pharmaceuticals Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Recursion Pharmaceuticals's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Recursion Pharmaceuticals (MEX:RXRX) has a Buyback Yield % of -25.78 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #549 out of 742 companies in the Biotechnology industry, placing it in the top 74%.
Is Recursion Pharmaceuticals' Buyback Yield % too high?
Recursion Pharmaceuticals' current Buyback Yield % is -25.78. Based on the distribution chart, Recursion Pharmaceuticals ranks #549 out of 742 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Buyback Yield % compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #549 out of 742 companies for Buyback Yield %. This places Recursion Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Buyback Yield % is -25.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current Buyback Yield % is -25.78. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Buyback Yield % is -25.78 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?
Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued.
The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63.
GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for MEX:RXRX:
Buyback Yield %: -25.78
GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score
Get the complete analysis for MEX:RXRX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:RXRX has been successfully added to your 
